SCHEMBL29267273

SCHEMBL29267273

CCOC(=O)c1cnc2c(Cl)cc(Br)cn12

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 3/20 0.42
LMNA P02545 3/20 0.42
KMT2A Q03164 2/20 0.39
NOTUM Q6P988 1/20 0.39
BAZ2B Q9UIF8 1/20 0.39
BAZ2A Q9UIF9 1/20 0.39
NPC1 O15118 5/20 0.39
RAB9A P51151 4/20 0.39
GABRA2 P47869 1/20 0.39
GABRB2 P47870 1/20 0.39
ALDH1A1 P00352 2/20 0.37
MAPT P10636 2/20 0.37
TP53 P04637 1/20 0.37
XBP1 P17861 1/20 0.37
MAPK1 P28482 1/20 0.37
HTT P42858 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
HSD17B10 Q99714 1/20 0.37
TLR9 Q9NR96 1/20 0.37
KDM4E B2RXH2 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30967371 0.85 IDO1 (0.42) IDO1LMNAKMT2ANPC1RAB9A
SCHEMBL17093165 0.82 LMNA (0.45) IDO1LMNAKMT2ANOTUMBAZ2B
SCHEMBL30357457 0.81 NPC1 (0.40) IDO1LMNAKMT2ANOTUMBAZ2B
SCHEMBL29267302 0.79 KDM4E (0.35) KMT2AALDH1A1MAPTKDM4EMEN1
SCHEMBL17093201 0.79 IDO1 (0.44) IDO1LMNANPC1RAB9AALDH1A1
SCHEMBL31258781 0.78 WDR5 (0.41) LMNAKMT2ANOTUMBAZ2BBAZ2A
SCHEMBL29267250 0.77 KDM4E (0.38) LMNAKMT2ANPC1ALDH1A1MAPT
SCHEMBL17093206 0.77 TGFBR1 (0.41) IDO1LMNANPC1RAB9AGABRA2
SCHEMBL29277603 0.77 IDO1 (0.40) IDO1LMNANPC1RAB9AGABRA2
SCHEMBL27389813 0.77 WDR5 (0.41) LMNAKMT2ANOTUMBAZ2BBAZ2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026104998-A1 SUBSTITUTED IMIDAZOPYRIDINE COMPOUND DERIVATIVES AND THEIR PHARMACEUTICAL USE AVELOS THERAPEUTICS INC. (KR) 2026-05-21 WO disclosed
EP-4716532-A2 BICYCLIC HETEROARYL COMPOUNDS Quantx Biosciences US, Inc. (US) 2026-04-01 EP disclosed
EP-4688159-A1 PARG INHIBITORY COMPOUNDS FoRx Therapeutics AG (CH) 2026-02-11 EP disclosed
US-20240425498-A1 PARG INHIBITORY COMPOUNDS FORX THERAPEUTICS AG (CH) 2024-12-26 US disclosed
WO-2024243304-A2 BICYCLIC HETEROARYL COMPOUNDS QUANTX BIOSCIENCES US, INC. (US) 2024-11-28 WO disclosed
WO-2024209035-A1 PARG INHIBITORY COMPOUNDS FORX THERAPEUTICS AG (CH) 2024-10-10 WO disclosed
EP-4413001-A1 PARG INHIBITORY COMPOUNDS FoRx Therapeutics AG (CH) 2024-08-14 EP disclosed
CN-118055934-A PARG inhibitory compounds 福克斯治疗股份公司 2024-05-17 CN disclosed
WO-2023057389-A1 PARG INHIBITORY COMPOUNDS FORX THERAPEUTICS AG (CH) 2023-04-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240425498-A1 PARG INHIBITORY COMPOUNDS PARG, PLG, PPIG IDO1 182/4885LMNA 594/4885KMT2A 1679/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.